NeuroRX, a clinical-stage biopharma company developing the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation or Behavior, will present phase 2 efficacy results from its...

As a not-for-profit serving the defense and intelligence communities, Riverside Research is excited to exhibit in this year's 2019 Geospatial Intelligence (GEOINT) Symposium and present two...

Vectrus, Inc. (NYSE: VEC), announced that company management will address the Stifel 2019 Cross Sector Insight Conference in Boston on Wednesday, June 12, at 9:45 a.m. Eastern time, and meet with...

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from the first cohort of a pivotal phase...

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and...